SEC Filing Analysis: Natera, Inc. (NTRA)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Co-Founder and Director Matthew Rabinowitz filed Form 144 for the intended sale of 200,000 common shares valued at approximately $65.23 million under a pre-established Rule 10b5-1 plan.
• Market Impact: Neutral; while substantial in nominal dollar terms, the proposed sale represents ~0.14% of shares outstanding and is executed under a programmatic plan.

Company Information

Field	Value
Company	Natera, Inc.
Ticker Symbol	NTRA
CIK	0001604821
Industry	Services - Medical Laboratories

Insider Information

Field	Value
Name	Matthew Rabinowitz
CIK	0001646382
Title/Position	Director & Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	Form 144
Transaction Date	2026-09-11
Transaction Code	Proposed Sale (S)
Security Type	Common Stock
Shares Involved	200,000
Price Per Share	$326.14
Total Value	$65,228,000.00
Shares Owned After	N/A (Form 144 notice)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$65,228,000.00
% of Market Cap	0.14%
Shares Transacted	200,000
% of Shares Outstanding	0.14%
Materiality Assessment	Moderate

Impact Evaluation

• Market Cap Context: Against Natera's $47.18 billion market capitalization, the $65.23M proposed transaction accounts for 0.14% of equity value, falling into the moderate materiality bracket.
• Dilution Impact: The shares to be sold originated from stock options exercised between May and November 2024, causing no immediate new dilution upon secondary sale.
• Transaction Significance: The transaction size is notable in absolute dollar terms but well within standard liquidation ranges for long-tenured company founders relative to overall market cap.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The planned transaction is governed by a Rule 10b5-1 trading plan established on June 12, 2026, mitigating concerns regarding opportunistic timing or unannounced fundamental developments.

Volume & Sentiment

• Expected Volume Impact: Low to Moderate absorbed across multiple trading sessions by Morgan Stanley.
• Sentiment Indicator: Neutral

Additional Context

Transaction Notes

• Special Circumstances: Notice filed pursuant to Rule 144 for shares acquired via option exercises. The filer adopted a 10b5-1 trading plan on June 12, 2026.
• Prior Activity: In the preceding three months, the reporting person and associated trusts executed sales of approximately 103,449 shares generating over $22.3M in gross proceeds.